HoldsUp

FoundMyFitness · 2025-07-15 · Ben Bikman

Dr. Ben Bikman: How To Reverse Insulin Resistance Through Diet, Exercise, & Sleep

100 research-tied claims examined: 13 contradicted 9 overstated 17 context 52 supported 9 unverified

13

Contradicted by research

0:20:05Ben Bikmancontradictedmoderate

Elevated insulin directly inhibits the aromatase enzyme, impairing the conversion of testosterone into estrogens in the ovary.

"Insulin has a direct inhibitory role on aromatase, that enzyme that mediates the conversion and the synthesis of estrogens in men and women." (said at 0:20:05)

The claim that insulin has a direct inhibitory effect on aromatase contradicts established endocrinological literature. Rather than inhibiting aromatase (the enzyme that converts androgens to estrogens), insulin enhances or induces aromatase expression and activity in peripheral tissues such as adipose tissue and bone. In men and postmenopausal women with hyperinsulinemia and obesity, elevated insulin promotes adipose aromatase activity, driving increased conversion of testosterone into estrogens rather than impairing it.

0:20:51Ben Bikmancontradictedlow

Cultured fat cells will not expand or accumulate lipid droplets from surrounding calories in vitro until insulin is introduced.

"Everything the fat cell needs—all the calories that fat cell could ever want are around it right now. And yet they're teeny little cells. They're not getting big at all until we add one thing. And the moment we add insulin into that culture, now the fat cells start to get big. If we check them 6 hours later, there's a big lipid droplet." (said at 0:20:51)

The claim asserts that cultured fat cells cannot expand or accumulate lipid droplets in vitro from available nutrients until insulin is added. However, in vitro research on adipocyte biology demonstrates that fat cells can take up exogenous free fatty acids and accumulate lipid droplets independently of insulin. In fact, experimental studies investigating lipid droplet enlargement from fatty acids (such as oleic acid) show that lipid accumulation occurs in culture and that insulin is not an absolute requirement for droplet formation; in some direct culture models, adding insulin actually attenuated fatty acid-induced lipid droplet enlargement.

  • contradicts: Insulin prevents fatty acid induced increase of adipocyte size. (Adipocyte 2022) · cited 16x in the literature
    "Using realtime 2D cell culture analyses of lipid uptake, we show (1) that high glucose concentration (4.5 g/L) was required to accumulate oleic acid increasing lipid droplet size until unilocularization similar to mature adipocytes in few days, (2) oleic acid reduced Peroxisome-Proliferator Activated Receptor Gamma ( PPARG) gene transcription and (3) insulin counteracted oleic acid-induced increase of lipid droplet size." (abstract, results, passage verified)
    pubmedfull study (doi)
0:26:59Ben Bikmancontradictedhigh

Excreting ketones in breath and urine during ketosis causes the body to lose up to several hundred calories per day, contributing to a net waste of up to 800 calories per day.

"And when you're in ketosis, you're eliminating ketones through the breath and the urine. And every ketone that a person's breathing out or urinating out has a caloric value roughly similar to glucose. So you're just excreting calories from the body. So the net effect of all of that can be up to 800 or so calories a day that the person's just wasting." (said at 0:26:59)

The claim that ketone excretion in urine and breath during ketosis causes an energy waste of up to several hundred or 800 calories per day is contradicted by metabolic ward studies and reviews of dietary thermodynamics. Rigorous clinical trials measuring 24-hour energy expenditure in metabolic chambers show that switching to an isocaloric ketogenic diet produces only minor shifts in energy expenditure (around 57 to 150 kcal/day), with ketone excretion contributing negligible caloric loss, far below the asserted 800 calories per day.

0:02:01Ben Bikmancontradictedhigh

Administering exogenous insulin therapy to type 2 diabetics pushes insulin to supraphysiological levels and increases mortality risk.

"giving, say, a type 2 diabetic an insulin therapy. Now they're pushing the insulin from high to supraphysiological, all in an effort to control the glucose, little realizing that in the process you're actually killing them faster because so much of what kills the type 2 diabetic is not the hyperglycemia; it's the hyperinsulinemia and the insulin resistance." (said at 0:02:01)

The claim that administering exogenous insulin therapy to type 2 diabetics increases mortality risk ("killing them faster") due to hyperinsulinemia and insulin resistance is contradicted by high-certainty randomized controlled trial evidence. In the landmark ORIGIN trial (12,537 participants followed for a median of 6.2 years), basal insulin glargine targeted to normalize fasting glucose had a neutral effect on all-cause mortality and cardiovascular outcomes compared to standard care, without increasing mortality risk despite modest weight gain and increased hypoglycemic events.

0:32:22Ben Bikmancontradictedhigh

Palmitate is the primary saturated fatty acid produced by the liver via de novo lipogenesis.

"When the liver is told to make fat through de novo lipogenesis, the fat that it makes is palmitate. So most of the fat, most of the saturated fat we have flowing through our blood that's going to get to a cell is going to be coming from what the liver is making, not from what we're eating." (said at 0:32:22)

The speaker's statement combines two distinct claims: (1) that palmitate is the primary fat synthesized by hepatic de novo lipogenesis (DNL), and (2) that most circulating (saturated) fat originates from hepatic DNL rather than dietary intake or adipose stores. While the first claim is biochemically accurate—palmitate (palmitic acid) is the primary product synthesized via fatty acid synthase during DNL—the second claim is contradicted by human metabolic tracer studies. Stable isotope kinetic studies consistently demonstrate that hepatic DNL accounts for only a minor fraction (typically ~3% to 5% in lean, healthy individuals, and ~10% to 25% in individuals with obesity, insulin resistance, or steatohepatitis) of circulating fatty acids and VLDL triglycerides. The vast majority of circulating saturated and non-esterified fatty acids originate from adipose tissue lipolysis (systemic NEFA) and dietary intake.

0:36:56Ben Bikmancontradictedmoderate

Fructose does not directly elicit an insulin response.

"No, fructose itself will not elicit an insulin response whatsoever." (said at 0:36:56)

While fructose does not directly stimulate pancreatic beta-cell insulin exocytosis through standard glucose-sensing pathways to the same extent as glucose, the claim that fructose does not elicit an insulin response 'whatsoever' is contradicted by in vivo findings. Ingestion of fructose acutely stimulates circulating insulin release in both humans and preclinical models. This physiological insulin response is primarily mediated through an indirect gut-pancreas axis, where intestinal fructose metabolism triggers the secretion of glucagon-like peptide-1 (GLP-1), which in turn stimulates pancreatic insulin secretion.

1:11:12Ben Bikmancontradictedlow

Chemicals such as diethylstilbestrol and bisphenol A (BPA) have been shown to promote adipose tissue expansion independent of changes in caloric intake.

"We've not done work on microplastics or the plasticizers, those like diethylstilbestrol and and BPA, but those also have been shown to promote greater fat expansion in the absence of calorie changes." (said at 1:11:12)

The assertion that endocrine disruptors like bisphenol A (BPA) and diethylstilbestrol (DES) promote adipose tissue expansion independent of changes in caloric intake is contradicted by rodent evidence demonstrating that early-life exposure alters hypothalamic feeding circuits, leading to increased food intake (hyperphagia). In CD-1 mice exposed perinatally to BPA, adult female offspring developed increased adiposity and body weight specifically alongside increased food consumption ('ate more') when fed a high-fat diet, rather than expanding fat mass in the absence of calorie changes.

1:38:05Ben Bikmancontradictedhigh

The United States ranks around 70th in the world for diabetes prevalence, while Singapore ranks around 9th and Middle Eastern countries occupy ranks 1 through 8.

"I think the US ranks somewhere in the 70s of, if you look at all the countries in the world and how diabetic they are, we're about number 70. Whereas Singapore, for example, and Japan is not too far back—Singapore is I think number nine, and all the countries of the Middle East are actually numbers one through eight, like Oman, Dubai, Jordan, these countries in the Middle East." (said at 1:38:05)

Global epidemiological data on adult diabetes prevalence (such as pooled analyses from the NCD Risk Factor Collaboration published in The Lancet and the International Diabetes Federation Atlas) contradict the speaker's specific ranking claims. Pacific island nations in Polynesia and Micronesia (such as American Samoa, Nauru, and Marshall Islands) consistently have the highest age-standardised diabetes prevalence in the world (exceeding 25–30%), rather than Middle Eastern countries occupying ranks 1 through 8 exclusively. Furthermore, Singapore does not rank 9th globally, and Japan has among the lowest prevalence rates in the developed world, particularly among women. Additionally, Dubai is a city/emirate within the United Arab Emirates, not an independent country.

1:46:15Ben Bikmancontradictedhigh

Adipose tissue is the primary source of plasminogen activator inhibitor-1 (PAI-1) in the body.

"And and and the fat cell is the main source of a protein called plasminogen activator inhibitor-1, PAI-1, whose main job is to erode clots as they form." (said at 1:46:15)

The speaker's statement contains two distinct assertions with contrasting accuracy. While visceral adipose tissue is indeed a major source of plasminogen activator inhibitor-1 (PAI-1), particularly in state of obesity, the claim regarding PAI-1's biological function is inverted. PAI-1 does not erode blood clots; rather, as an inhibitor of tissue plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA), its function is to suppress fibrinolysis and prevent the breakdown of blood clots, thereby promoting clot persistence.

2:02:34Ben Bikmancontradictedmoderate

Fat cell turnover declines in older age (around 60 to 70 years old), leading to a net reduction in the total number of fat cells.

"But then when we get to older age, then the number of fat cells stop turning over. So as they start dying at their 10-year lifespan, we don't replace them. And so at the end of life we have a little drop off in the number of fat cells." (said at 2:02:34)

The speaker claims that fat cell turnover ceases in older age, resulting in fat cells dying after their ~10-year lifespan without replacement and leading to a drop-off in total fat cell number at the end of life. Landmark human studies measuring adipocyte turnover via bomb-pulse 14C dating demonstrate that adipocyte number remains constant throughout adulthood, and fat cell renewal continues at approximately 10% per year across all adult ages. While lipid turnover (the rate of lipid removal and storage within fat cells) decreases with age (as shown by Arner et al., 2019), fat cell turnover itself does not stop, and there is no evidence of a total fat cell drop-off due to unreplaced adipocyte death in older age.

2:12:15Ben Bikmancontradictedhigh

Arne Astrup has published multiple human studies demonstrating that GLP-1 does not stimulate insulin secretion or act as an insulin secretagogue in humans.

"Now some people have the very mistaken view that semaglutide or GLP-1 activators also release insulin. That is not true. That has been shown to happen in isolated cell cultures, but in humans there's no evidence. And the authority on the subject is a guy named Arne Astrup in Denmark. He's one of the absolute authorities on this topic. He's published multiple papers in humans showing that no amount of GLP-1 elicits an insulin release." (said at 2:12:15)

The claim is contradicted by extensive physiological and clinical trial evidence in humans. Glucagon-like peptide-1 (GLP-1) is an incretin hormone whose hallmark biological action is the glucose-dependent stimulation of insulin secretion from pancreatic beta cells. Decades of human studies, including randomized controlled trials and hyperglycemic clamp experiments, demonstrate that intravenous infusion of GLP-1 as well as GLP-1 receptor agonists (such as semaglutide) robustly stimulate insulin secretion in both healthy individuals and patients with type 2 diabetes. Arne Astrup's published human studies on GLP-1 focus primarily on appetite regulation, gastric emptying, and energy intake rather than claiming that GLP-1 fails to elicit insulin release.

2:32:10Ben Bikmancontradictedmoderate

A single dose of insulin activates mTOR for up to 24 hours, whereas leucine only activates mTOR for approximately one to two hours.

"One dose of insulin can activate mTOR for up to 24 hours. Whereas leucine, the most anabolic of the amino acids, will only activate mTOR for about an hour or two." (said at 2:32:10)

While leucine stimulates the mTOR pathway and downstream protein synthesis transiently for approximately 1 to 3 hours (often referred to as the 'muscle full' effect), there is no evidence that a single physiological dose of insulin sustains mTOR activation for up to 24 hours. Both hormonal (insulin) and amino acid signaling pathways regulate muscle protein turnover on a acute timescale of minutes to hours rather than sustained across an entire day from a single dose.

2:37:07Ben Bikmancontradictedhigh

Giving insulin therapy to type 2 diabetic patients triples their risk of dying from heart disease and doubles their risk of dying from cancer.

"When you give a type 2 diabetic insulin therapy, they get fatter and sicker and die faster, all while glucose looks good. This is well documented. Their risk of dying from heart disease triples. Their risk of dying from cancer doubles when you give them insulin." (said at 2:37:07)

The claim that insulin therapy triples the risk of cardiovascular death and doubles the risk of cancer death in patients with type 2 diabetes is contradicted by randomized controlled trial evidence. In the large-scale ORIGIN trial (12,537 participants followed for over 6 years), basal insulin therapy showed a completely neutral effect on cardiovascular outcomes (HR 1.02, 95% CI 0.94–1.11) as well as cancer incidence (HR 1.00, 95% CI 0.88–1.13) and cancer-specific mortality compared with standard care. While observational studies sometimes report higher mortality among insulin users, this reflects confounding by indication (insulin is prescribed to patients with longer disease duration, more advanced comorbidities, and poorer baseline health), not a causal doubling or tripling of mortality.

Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.